|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Carr BI: Hepatocellular carcinoma: current
management and future trends. Gastroenterology. 127:S218–S224.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patt YZ, Hassan MM, Aguayo A, et al: Oral
capecitabine for the treatment of hepatocellular carcinoma,
cholangiocarcinoma and gallbladder carcinoma. Cancer. 101:578–586.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin DY, Lin SM and Liaw YF: Non-surgical
treatment of hepatocellular carcinoma. J Gastroenterol Hepatol.
12:S319–S328. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: a new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
|
|
6
|
Larsson O, Morita M, Topisirovic I, et al:
Distinct perturbation of the translatome by the antidiabetic drug
metformin. Proc Natl Acad Sci USA. 109:8977–8982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
from growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang N, Pan W, Zhu M, et al: Fangchinoline
induces autophagic cell death via p53/sestrin2/AMPK signalling in
human hepatocellular carcinoma cells. Br J Pharmacol. 164:731–742.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang DM, Liu JS, Deng LJ, et al:
Arenobufagin, a natural bufadienolide from toad venom, induces
apoptosis and autophagy in human hepatocellular carcinoma cells
through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis.
34:1331–1342. 2013. View Article : Google Scholar
|
|
10
|
Cui XD, Lee MJ, Kim JH, et al: Activation
of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by
growth factor-mediated Eph receptor 2 (EphA2) is required for
cholangiocarcinoma growth and metastasis. Hepatology. 57:2248–2260.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishikawa T, Takaoka M, Ohara T, et al:
Antiproliferative effect of a novel mTOR inhibitor temsirolimus
contributes to the prolonged survival of orthotopic esophageal
cancer-bearing mice. Cancer Biol Ther. 14:230–236. 2013. View Article : Google Scholar
|
|
12
|
Reungwetwattana T, Molina JR, Mandrekar
SJ, et al: Brief report: a phase II “window-of-opportunity”
frontline study of the MTOR inhibitor, temsirolimus given as a
single agent in patients with advanced NSCLC, an NCCTG study. J
Thorac Oncol. 7:919–922. 2012.
|
|
13
|
Grgic T, Mis L and Hammond JM: Everolimus:
a new mammalian target of rapamycin inhibitor for the treatment of
advanced renal cell carcinoma. Ann Pharmacother. 45:78–83. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakabayashi M, Werner L, Courtney KD, et
al: Phase II trial of RAD001 and bicalutamide for
castration-resistant prostate cancer. BJU Int. 110:1729–1735. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sullivan R, Pare GC, Frederiksen LJ,
Semenza GL and Graham CH: Hypoxia-induced resistance to anticancer
drugs is associated with decreased senescence and requires
hypoxia-inducible factor-1 activity. Mol Cancer Ther. 7:1961–1973.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kunz M and Ibrahim SM: Molecular responses
to hypoxia in tumor cells. Mol Cancer. 2:232003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Liu G, Lin C, Liao G and Tang B:
Silencing the EZH2 gene by RNA interference reverses the drug
resistance of human hepatic multidrug-resistant cancer cells to
5-Fu. Life Sci. 92:896–902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller RA and Birnbaum MJ: An energetic
tale of AMPK-independent effects of metformin. J Clin Invest.
120:2267–2270. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiong Y, Lu QJ, Zhao J and Wu GY:
Metformin inhibits growth of hepatocellular carcinoma cells by
inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J
Cancer Prev. 13:3275–3279. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu MM, Tong JL, Xu Q, et al: Increased
JNK1 signaling pathway is responsible for ABCG2-mediated multidrug
resistance in human colon cancer. PLoS One. 7:e417632012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thomas GV, Tran C, Mellinghoff IK, et al:
Hypoxia-inducible factor determines sensitivity to inhibitors of
mTOR in kidney cancer. Nat Med. 12:122–127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu H, Luo SF, Wang J, et al: Effect of
environmental factors on chemoresistance of HepG2 cells by
regulating hypoxia-inducible factor-1alpha. Chin Med J (Engl).
125:1095–1103. 2012.PubMed/NCBI
|
|
23
|
Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK
and Chen GF: Regulation of hypoxia inducible factor-1alpha
expression by the alteration of redox status in HepG2 cells. J Exp
Clin Cancer Res. 30:612011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takiyama Y, Harumi T, Watanabe J, et al:
Tubular injury in a rat model of type 2 diabetes is prevented by
metformin: a possible role of HIF-1alpha expression and oxygen
metabolism. Diabetes. 60:981–992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan
E and Oktay TM: Use of oral antidiabetic drugs (metformin and
pioglitazone) in diabetic patients with breast cancer: how does it
effect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev.
13:5143–5148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zannella V, Dal Pra A, Muaddi H, et al:
Reprogramming metabolism with metformin improves tumor oxygenation
and radiotherapy response. Clin Cancer Res. 19:6741–6750. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sheng B, Liu J and Li GH: Metformin
preconditioning protects Daphnia pulex from lethal hypoxic
insult involving AMPK, HIF and mTOR signaling. Comp Biochem Physiol
B Biochem Mol Biol. 163:51–58. 2012.PubMed/NCBI
|
|
28
|
Li Y and Ye D: Cancer therapy by targeting
hypoxia-inducible factor-1. Curr Cancer Drug Targets. 10:782–796.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rho JK, Choi YJ, Lee JK, et al: Gefitinib
circumvents hypoxia-induced drug resistance by the modulation of
HIF-1alpha. Oncol Rep. 21:801–807. 2009.PubMed/NCBI
|
|
30
|
Huang C, Xu D, Xia Q, Wang P, Rong C and
Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of
human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol.
64:1741–1750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding Z, Yang L, Xie X, et al: Expression
and significance of hypoxia-inducible factor-1 alpha and
MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J
Cancer Res Clin Oncol. 136:1697–1707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li DW, Dong P, Wang F, Chen XW, Xu CZ and
Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer
cells via hypoxia-inducible factor-1alpha. Asian Pac J Cancer Prev.
14:4853–4858. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen M, Huang SL, Zhang XQ, et al:
Reversal effects of pantoprazole on multidrug resistance in human
gastric adenocarcinoma cells by down-regulating the
V-ATPases/mTOR/HIF-1alpha/P-gp and MRP1 signaling pathway in vitro
and in vivo. J Cell Biochem. 113:2474–2487. 2012. View Article : Google Scholar
|
